Foghorn Therapeutics Moves Headquarters from Kendall Square to Watertown
Biotech company Foghorn Therapeutics Inc. is relocating its headquarters from Cambridge to Watertown. In a recent securities filing, the company announced it will terminate its lease in Kendall Square early and lease 72,850 square feet at 99 Coolidge Avenue in Watertown for executive offices, research, development, manufacturing, and other operations. The Watertown lease begins July 16, 2025.
The new building, a 255,000-square-foot life science facility developed by Alexandria Real Estate Equities and National Development on the former Mount Auburn Club site, offers state-of-the-art facilities and expanded lab space.
Foghorn is exiting its lease at 500 Technology Square in Cambridge, where it occupies about 81,440 square feet until September 2028. The company said the move provides a better footprint for its current structure, shorter commutes for most employees, and near-term real estate cost savings. Foghorn currently employs 112 full-time workers.
Founded in 2018 by Flagship Pioneering, Foghorn develops therapies targeting abnormal gene expression, with a focus on cancers. Its only clinical program is in collaboration with Loxo Oncology at Eli Lilly, including the February 2024 announcement that Lilly selected FHD-909 for clinical development in patients with BRG1-mutated non-small cell lung cancer.